Form 4: Madrigal Pharmaceuticals General Counsel Shannon T. Kelley Reports Sale of Common Stock

Shannon T. Kelley, General Counsel of Madrigal Pharmaceuticals, sold 415 shares of common stock at $335 per share on March 3, 2025, according to a Form 4 filing.

Summary

• On March 3, 2025, Shannon T. Kelley, the General Counsel of Madrigal Pharmaceuticals, sold 415 shares of common stock.
• The sale was executed at a price of $335 per share.
• Following the transaction, Kelley directly owns 7,290 shares of Madrigal Pharmaceuticals.
• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2024.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a stock sale by a company insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transaction.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider transactions and are closely watched by investors for signals about a company's prospects.

Stakeholder Impact

• The stock sale by a company insider may be perceived differently by stakeholders.
• Some may view it as a lack of confidence in the company's future, while others may see it as a routine transaction under a pre-arranged trading plan.

Key Dates